Methodological considerations in D-health cancer mortality results - Authors' reply

Affiliations

¹ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: rachel.neale@qimrberghofer.edu.au.
² Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
³ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
⁴ Melbourne School of Population Health, University of Melbourne, Melbourne, VIC, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
⁵ School of Exercise and Nutrition Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
⁶ Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
⁷ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; School of Public Health, University of Queensland, Brisbane, QLD, Australia.

Comment

Rachel E Neale et al. Lancet Diabetes Endocrinol. 2022 May.

. 2022 May;10(5):307-308.

doi: 10.1016/S2213-8587(22)00107-3.

¹ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: rachel.neale@qimrberghofer.edu.au.
² Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
³ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
⁴ Melbourne School of Population Health, University of Melbourne, Melbourne, VIC, Australia; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
⁵ School of Exercise and Nutrition Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
⁶ Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
⁷ Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; School of Public Health, University of Queensland, Brisbane, QLD, Australia.

No abstract available

Conflict of interest statement

PMW reports funding from AstraZeneca for an unrelated study on ovarian cancer. All other authors declare no competing interests.

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality.
Neale RE, Baxter C, Romero BD, McLeod DSA, English DR, Armstrong BK, Ebeling PR, Hartel G, Kimlin MG, O'Connell R, van der Pols JC, Venn AJ, Webb PM, Whiteman DC, Waterhouse M. Neale RE, et al. Lancet Diabetes Endocrinol. 2022 Feb;10(2):120-128. doi: 10.1016/S2213-8587(21)00345-4. Epub 2022 Jan 10. Lancet Diabetes Endocrinol. 2022. PMID: 35026158 Clinical Trial.
Methodological considerations in D-health cancer mortality results.
Egger S, Smith DP, Nair-Shalliker V. Egger S, et al. Lancet Diabetes Endocrinol. 2022 May;10(5):307. doi: 10.1016/S2213-8587(22)00109-7. Lancet Diabetes Endocrinol. 2022. PMID: 35461532 No abstract available.